Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.16M Sell
3,208
-222
-6% -$76K 0.34% 56
2026
Q1
$1.21M Buy
3,430
+50
+1% +$17.8K 0.38% 54
2025
Q4
$1.11M Sell
3,380
-80
-2% -$25.4K 0.33% 60
2025
Q3
$976K Sell
3,460
-9
-0.3% -$2.61K 0.29% 66
2025
Q2
$969K Sell
3,469
-895
-21% -$254K 0.3% 65
2025
Q1
$1.36M Buy
4,364
+126
+3% +$37.2K 0.43% 51
2024
Q4
$1.1M Buy
+4,238
New +$1.26M 0.34% 58
2024
Q2
$1.3M Sell
4,163
-477
-10% -$140K 0.41% 48
2024
Q1
$1.32M Buy
4,640
+5
+0.1% +$1.46K 0.4% 49
2023
Q4
$1.33M Buy
4,635
+143
+3% +$39K 0.43% 48
2023
Q3
$1.21M Buy
4,492
+193
+4% +$48.2K 0.43% 46
2023
Q2
$1.13M Buy
+4,299
New +$998K 0.38% 48
2019
Q3
$1.33M Buy
+4,139
New +$794K 0.4% 51

Other funds holding AMGN

PFW Advisors's AMGN Position: Q2 2026 in Review

PFW Advisors reduced its Amgen (AMGN) stake by 6.5% in Q2 2026, selling an estimated $76K and leaving 3,208 shares worth $1.16M. The position accounts for 0.34% of the portfolio, ranked #56.

PFW Advisors first reported a position in AMGN in Q3 2019 and has held it in 13 quarters since. The position peaked at $1.36M in Q1 2025. 748 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • PFW Advisors held 3,208 shares of Amgen worth $1.16M as of Q2 2026.
  • PFW Advisors sold 222 Amgen shares in Q2 2026, an estimated $76K.
  • Amgen made up 0.34% of PFW Advisors's portfolio in Q2 2026, its #56 holding.
  • PFW Advisors first reported a position in Amgen in Q3 2019 and has held it in 13 quarters since.
  • PFW Advisors's Amgen position peaked at $1.36M in Q1 2025.
  • 748 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on PFW Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.